Alchemia establishes level 1 ADR program
Friday, 20 August, 2004
Brisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
Managing director Dr Tracie Ramsdale said a NASDAQ listing was a natural extension of the company’s increasing focus on the United States, which was the primary market for its future products.
Earlier this month, Alchemia completed the scale-up of the manufacturing process for its synthetic heparin, which it is developing with partners Dow Chemical and American Pharmaceutical Partners.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
